Download PDF

Other users also viewed these articles

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;
Nefrologia (English Version). 2024;44:857-67
Spanish Registry of Renal Patients: 2022 Report and evolutive analysis Borja Quiroga; Beatriz Mahíllo; Auxiliadora Mazuecos; Alberto Ortiz; Jordi Comas Farnés; Domingo Hernández Marrero; Sara Trujillo Alemán; M. Carmen Santiuste de Pablos; Olga Lucía Rodríguez Arévalo; María Marques Vidas; M. Fernanda Slon-Roblero; Marta Artamendi Larrañaga; Iñigo Moina Eguren; María de la Oliva Valentín Muñoz; Marta Rodríguez Camblor; Inmaculada Moreno Alia; Mª Encarnación Bouzas Caamaño; Mª Antonia Blanco Galán; Javier Deira Lorenzo; Héctor García López; Federico Eduardo Arribas Monzon; Gonzalo Gómez Marqués; Alberto Rodríguez-Benot; Beatriz Domínguez-Gil; Emilio Sánchez Álvarez;
10.1016/j.nefroe.2025.03.002
Cardiovascular-kidney-metabolic syndrome definition and its role in the prevention, risk staging, and treatment. An opportunity for the Nephrology Aleix Cases; Jose Jesus Broseta; Maria Marqués; Secundino Cigarrán; Juan Carlos Julián; Roberto Alcázar; Alberto Ortiz;
Nefrologia (English Version). 2024;44:771-83